Volition

VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update

Retrieved on: 
Wednesday, November 9, 2022
Investor relations, Patient, NYSE, Conference call, Eastern Time Zone, Group, Life, Disease, COVID-19, Sepsis, Neutrophil extracellular traps, Science, Research, Quality of life, Cancer, Conference, Nucleosome, Volition

HENDERSON, Nev., Nov. 9, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday November 15 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the third quarter 2022, in addition to providing a business update.

Key Points: 
  • Conference call to take place on Tuesday November 15 at 08:30 a.m. Eastern Time
    HENDERSON, Nev., Nov. 9, 2022 /PRNewswire/-- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday November 15 at 08.30 a.m. Eastern Time to discuss its financial and operating results for the third quarter 2022, in addition to providing a business update.
  • The call will provide an update on important events which have taken place in the third quarter of 2022 and upcoming milestones.
  • A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com .
  • In addition, a telephone replay of the call will be available until November 29, 2022.

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Lymphoma, Security (finance), Veterinarian, U.S. Securities and Exchange Commission, Forward-looking statement, Software, COVID-19, Dog, Securities Act of 1933, Neutrophil extracellular traps, Trial of the century, Professor, Sepsis, Research, HSKA, Technology, Achievement, PETS, Texas A&M University, Name, Patient, Quality of life, Cancer, Annual report, Animal, Hemangiosarcoma, Immunotherapy, Science, Life, Health, License, Volition (company), Disease, NYSE, Histiocytic sarcoma, Securities Exchange Act of 1934, Human, Pharmaceutical industry, Medical device, International, Volition, Nucleosome

The accurate, affordable, and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska's expanding portfolio of best-in-class solutions.

Key Points: 
  • The accurate, affordable, and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska's expanding portfolio of best-in-class solutions.
  • Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said, "We're thrilled to be working alongside Heska and support the launch of the Nu.QVet Cancer Screening Test in the United States and Europe.
  • Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
  • All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

EQS-News: Lenzing AG: Nico Reiner appointed new Chief Financial Officer of Lenzing AG

Retrieved on: 
Thursday, November 3, 2022
Marketing, HHL Leipzig Graduate School of Management, Growth, Volition, Lenzing AG, University of Regensburg, CFO, University, Regensburg, Supervisory board, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Management, Lenzing

Nico Reiner to succeed Thomas Obendrauf on January 1, 2023

Key Points: 
  • Nico Reiner to succeed Thomas Obendrauf on January 1, 2023
    Lenzing The Supervisory Board of Lenzing AG, a world-leading provider of sustainably produced specialty fibers for the textile and nonwoven industries, has appointed Nico Reiner as its new Chief Financial Officer.
  • Mr. Reiner will join Lenzings Managing Board led by Chief Executive Officer Stephan Sielaff on January 1, 2023.
  • He will succeed Chief Financial Officer Thomas Obendrauf, who is leaving the company of his own volition after seven years.
  • We are delighted to welcome Nico Reiner to the Managing Board of Lenzing as he is a proven financial expert with substantial international experience.

Parade Integrates with TruckSmarter to Better Enable Freight Brokers

Retrieved on: 
Tuesday, October 18, 2022
SAN, ARL, Volition, LLC, Entrepreneurship, Partnership, Artificial intelligence, Software, Industry, CEO, Ecosystem, Remake, GLOBE, Digital, Cargo, Parade

Now, TruckSmarter drivers can gain real-time access to leading freight brokers, and those brokers can use the Parade platform to expand their carrier network and quickly book freight with drivers via TruckSmarter.

Key Points: 
  • Now, TruckSmarter drivers can gain real-time access to leading freight brokers, and those brokers can use the Parade platform to expand their carrier network and quickly book freight with drivers via TruckSmarter.
  • Parade provides the much-needed backbone for freight brokers to help them meet drivers where they are.
  • Our partnership between TruckSmarter and Parade enables freight brokers more digital access to carriers to find more capacity and to expand their carrier networks, said Anthony Sutardja, CEO and Co-Founder of Parade.
  • Parade enables freight brokers to access TruckSmarter carriers through a single-click, zero-implementation integration.

Power Home Remodeling Employees Raise Over $1.5 Million for Alex's Lemonade Stand Foundation

Retrieved on: 
Tuesday, October 11, 2022
Alex's Lemonade Stand Foundation, Volition, Education, Foundation, Hospital, Research, Partnership, Cancer, Power Home Remodeling Group, Awareness, Cure, Environment, Heroes, ALSF, Power, Pharmaceutical industry

CHESTER, Pa., Oct. 11, 2022 /PRNewswire-PRWeb/ -- Power Home Remodeling ("Power"), the nation's largest, full-service exterior home remodeler, announced today that its 3,000+ employees across the country have raised a record $1.5 million in donations for Alex's Lemonade Stand Foundation (ALSF), a nonprofit dedicated to finding cures for various forms of childhood cancer. Over $1.1M was raised in the first day of the campaign alone in a record two-hour timespan, bringing Power's total contributions to ALSF over the last 11 years to more than $6 million, all entirely raised by employees of their own volition.

Key Points: 
  • "It has always made sense for Power to support Alex's Lemonade Stand Foundation because we've identified a charitable partner where authenticity, standards, and outlook are in lockstep with our mission to create positive change," said Adam Kaliner, co-Founder of Power Home Remodeling.
  • This year, Power has formally created the "Power The Cure" fund to reinforce its long-term commitment to this partnership.
  • Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra "Alex" Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer.
  • Established in 1992, Power is the nation's largest, full-service, exterior home remodeler with more than 3,000 employees, over one million lifetime customers, and $825 million in annual revenue.

VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th

Retrieved on: 
Monday, September 12, 2022
Human, COVID-19, NYSE, Sepsis, Life, Patient, Quality of life, Neutrophil extracellular traps, Science, Nucleosome, VIC, Research, GLOBE, Animal, EVP, Cancer, Disease, Volition, Security (finance), Medical device

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

Key Points: 
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
  • Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Arteza Enters Retail Space With JOANN Partnership

Retrieved on: 
Friday, September 2, 2022
Partnership, Wynwood, CEO, YouTube, Education, Creativity, Specialty store, Volition, Industry, Online shopping, Instagram, Facebook

MIAMI, Sept. 2, 2022 /PRNewswire/ -- Arteza, a rapidly scaling arts and crafts brand dedicated to championing all creators by providing premium yet affordable products and education that inspires boundless creativity, today announced its entrance into JOANN stores, a leading crafts retailer. Quickly ranked as one of the fastest-growing e-commerce brands globally, Arteza makes a pivotal move to enter the retail space.

Key Points: 
  • Quickly ranked as one of the fastest-growing e-commerce brands globally, Arteza makes a pivotal move to enter the retail space.
  • JOANN will sell Arteza products across 350 brick-and-mortar stores, as well as being available on the brand website.
  • "The ability to offer a tangible and immersive experience for our consumers across JOANN retail stores is a golden opportunity for us," said Erick Haskell, CEO at Arteza.
  • To learn more about Arteza, visit Arteza.com or follow Arteza on Instagram , Facebook , and YouTube .

Volition Appoints Mickie Henshall as an Independent Director

Retrieved on: 
Tuesday, August 16, 2022
Housing, Communities and Local Government Committee, NYSE, Diagnosis, Technology, Nomination, Cancer, Research, Life, Financial compensation, Marketing, Neutrophil extracellular traps, Patient, Quality of life, COVID-19, Associate, Sepsis, IVD, Science, Professional Football Compensation Committee, Illumina, Inc., Human, Animal, WGA, Disease, Management, Medical device, Volition, Nucleosome

HENDERSON, Nev., Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022.

Key Points: 
  • HENDERSON, Nev., Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022.
  • Ms. Henshall was also appointed as a member of the Compensation Committee and the Nominations and Governance Committee.
  • Dr. Martin Faulkes, Executive Chairman of Volition, said, "We're delighted to have attracted someone of Mickie's caliber to Volition's board.
  • Commenting on her appointment, Mickie Henshall said, "I'm joining Volition at a significant stage in the company's development with the Nu.Q Vet test recently licensed to Heska, an industry leader, and Nu.Q NETs achieving CE marking.

Volition Announces U.S. Clinical Study for NETs

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, Securities Act of 1933, Forward-looking statement, Failure, Securities Exchange Act of 1934, Security (finance), Research, Annual report, Life, Cancer, Quality of life, Patient, Neutrophil extracellular traps, Volition (linguistics), COVID-19, NETS, Sepsis, Science, Disease, Medical device, Volition, Nucleosome

Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.

Key Points: 
  • Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
  • These forward-looking statements relate to, among other topics, Volition's expectations related to the potential uses, benefits and effectiveness of its Nu.Q NETs test.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

VolitionRx Limited Schedules Second Quarter 2022 Earnings Conference Call and Business Update

Retrieved on: 
Monday, August 8, 2022
Investor relations, NYSE, Conference call, Eastern Time Zone, Research, Life, Cancer, Quality of life, Patient, Neutrophil extracellular traps, COVID-19, Sepsis, Science, Disease, Volition, Conference, Nucleosome

HENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday August 11, at 08.30 a.m. Eastern Time to discuss its financial and operating results for the second quarter 2022, in addition to providing a business update.

Key Points: 
  • Conference call to take place on Thursday August 11 at 08:30 a.m. Eastern Time
    HENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday August 11, at 08.30 a.m. Eastern Time to discuss its financial and operating results for the second quarter 2022, in addition to providing a business update.
  • The call will provide an update on important events which have taken place in the second quarter of 2022 and upcoming milestones.
  • A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com .
  • In addition, a telephone replay of the call will be available until August 25, 2022.